How FIMECS is Developing a New Class of Pharmaceuticals

The human body contains around 18 thousand proteins, 15 thousand of which are associated with diseases, yet only around 300 of these proteins are considered “druggable.” Anthony Lacavera joins Kanae Gamo, FIMECS Co-Founder and Chief Scientific Officer, to learn more about how the company is developing a new class of drugs based on targeted protein degradation therapy ⁠— a promising approach to use the natural mechanism of protein degradation to eliminate specific disease-causing proteins.